AKT1 and neoplasm: S1 shows aberrant WNT/TGF-β activation and greater early recurrence, S2 is a proliferation phenotype [MYC/protein kinase B (AKT) targets] with larger tumours and higher serum AFP, and S3 is a hepatocyte-differentiated phenotype with lower AFP and better differentiation.